Journal
JOURNAL FOR IMMUNOTHERAPY OF CANCER
Volume 11, Issue 8, Pages -Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/jitc-2022-006518
Keywords
Immunotherapy; Oncolytic Viruses; Antibodies; Neoplasm; Combined Modality Therapy
Categories
Ask authors/readers for more resources
Oncolytic viruses (OVs) have the potential to selectively kill tumor cells while amplifying the therapeutic agent within the tumor. Combination therapies, particularly with checkpoint inhibitor antibodies, have shown greater success than single agent treatments. This review examines the efficacy of encoding the antibodies within the OV genome versus administering them separately alongside OV treatments, and discusses key parameters influencing the superiority of these approaches.
Oncolytic viruses (OVs) provide the promise of tumor-selective cytotoxicity coupled with amplification of the therapeutic agent (the virus) in situ within the tumor improving its therapeutic index. Despite this promise, however, single agent-treatments have not been as successful as combination therapies, particularly combining with checkpoint inhibitor antibodies. The antibodies may be delivered by two approaches, either encoded within the OV genome to restrict antibody production to sites of active virus infection or alternatively given alongside OVs as separate treatments. Both approaches have shown promising therapeutic outcomes, and this leads to an interesting question of whether one approach is potentially better than the other. In this review, we provide a brief summary of the combination OV-antibody therapies that target tumor cells, tumor microenvironment and immune cells to help define key parameters influencing which approach is superior, thereby improving insight into the rational design of OV treatment strategies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available